Randomized, placebo-controlled phase 2 trial of a XXXX probiotic given intravaginally for prevention of recurrent @entity293 .

@entity1 @entity365 @entity293 @entity2335 @entity10265
BACKGROUND: @entity293 ( @entity293 ) are common among @entity1 and frequently recur. @entity365 is associated with UTI risk, which suggests that repletion may be beneficial. We conducted a double-blind placebo-controlled trial of a @entity10265 intravaginal suppository probiotic (Lactin-V; Osel) for prevention of recurrent UTI in premenopausal @entity1 . METHODS: One hundred young @entity1 with a history of recurrent UTI received antimicrobials for acute UTI and then were randomized to receive either Lactin-V or placebo daily for 5 d, then once weekly for 10 weeks. @entity1 were followed up at 1 week and 10 weeks after intervention and for @entity293 ; urine samples for culture and vaginal swabs for real-time quantitative 16S ribosomal RNA gene polymerase chain reaction for @entity10265 were collected. RESULTS: Recurrent UTI occurred in 7/48 15% of @entity1 receiving Lactin-V compared with 13/48 27% of @entity1 receiving placebo (relative risk [RR], .5; 95% confidence interval, .2-1.2). High-level vaginal colonization with @entity10265 (>= 10(6) 16S RNA gene copies per swab) throughout follow-up was associated with a significant reduction in recurrent UTI only for Lactin-V (RR for Lactin-V, .07; RR for placebo, 1.1; P < .01). CONCLUSIONS: Lactin-V after treatment for @entity2335 is associated with a reduction in recurrent UTI. Larger efficacy trials of this novel preventive method for recurrent UTI are warranted. CLINICAL TRIALS REGISTRATION. NCT00305227.
